
Rigetti Computing (RGTI) is aggressively expanding its commercialization efforts through strategic partnerships, including a Memorandum of Understanding with India's C-DAC for hybrid quantum hardware co-development, a five-year, $100 million joint investment with Quanta Computers, and quantum cloud service delivery in South Korea. These initiatives are expected to pave the way for new revenue streams and global market penetration. RGTI shares have gained 31% year-to-date, outperforming the industry, with 2025 earnings projected to rise 86.1%; however, the stock trades at a high price-to-book ratio of 11.7, suggesting a premium valuation.
Rigetti Computing (RGTI) is aggressively pursuing a commercialization strategy through a series of key global partnerships, positioning itself to capture new revenue streams. The new Memorandum of Understanding with India’s C-DAC for co-developing hybrid quantum systems strategically aligns with India's domestic "ChipIN" program. This follows several other significant 2025 initiatives, including a five-year, over $100 million joint investment with Quanta Computers, an 84-qubit quantum cloud service launch in South Korea with Norma Inc., and the installation of its first academic QPU at Montana State University. The market has reacted favorably to this momentum, with RGTI's stock price appreciating 31% year-to-date, outperforming the industry's 23.5% growth. This performance is underpinned by a consensus earnings estimate projecting an 86.1% rise in 2025. However, this growth outlook is accompanied by a very high valuation, with the company trading at a price-to-book ratio of 11.7 and holding a Zacks Value Score of 'F', indicating the stock is expensive on a fundamental basis. The neutral Zacks Rank of #3 (Hold) reflects this tension between strong strategic execution and a potentially stretched valuation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment